More than 10,00,000 new cases of skin nonmelanoma cancer has been reported for the current year only in U.S. This enhanced the market for anti skin cancer drugs and therapies within the dermatology market. Dermatology continues to remain one of the promising sectors within the pharmaceutical market due to recent drug developments in the respective area. Acne, dermatitis, psoriasis continue to generate major revenues for the market. Further, psoriasis is expected to grow at significant growth rates in the coming years due to numerous pipeline drugs awaiting FDA approvals such as Humira. The market challenges for the players in an era of increasing generic competition are to recognize attractive niche markets and efficient life cycle management. Also, innovative drugs or treatments are expected to drive the market to a great extent. Moreover, increased awareness on skin care and treatments are also impacting the market positively.
Browse in-depth TOC on World Dermatology Market (Drugs, Therapeutic Segments and Disorders) (2010 to 2015) http://www.marketsandmarkets.com/Market-Reports/dermatology-market-154.html
Each section of the report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints and opportunities. The report contains strategic section with respect to competitive landscape and market overview. The report will encompass more than 40 company profiles.